Viatris Eye Drops Data Shows Promise For Blurred Near Vision

All NewsJune 26, 2025

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent